Skip to content

Dr. Alexander Bondke
Dr. Alexander Bondke holds a PhD in synthetic chemistry from Imperial College London and is admitted as German Patent Attorney. He gained extensive experience in medicinal chemistry and is an inventor of CT7001, a cancer drug candidate in clinical trials.


Parcours technique
Dr. Bondke is one of the main inventors of the drug candidate CT7001 (aka ICEC0942), a selective kinase inhibitor currently evaluated in clinical trials for the treatment of multiple types of cancer. He serves as a member of the scientific advisory board of a pharmaceutical company and has experience as a scientific consultant.

Dr. Bondke holds a PhD in synthetic organic chemistry from Imperial College London (GB), which was funded by Cancer Research UK and focused on medicinal chemistry and drug discovery. During his PhD, he completed two research programmes at Emory University (US) and later became project manager of a drug discovery project at Imperial College London.

Additionally, he holds the degree of ‘Diplom-Chemiker’ (i.e., MSc in Chemistry) from Technical University of Berlin (DE) and carried out the research for his master’s thesis in natural product synthesis at Imperial College London (GB).

Activités juridiques
Dr. Bondke joined WRST in 2014 as a patent professional and is admitted as German Patent Attorney since 2018.

Dr. Bondke counsels pharmaceutical, chemical and biotech companies in matters relating to strategic patent prosecution, freedom to operate analyses, portfolio management, patentability, and patent infringement. He has experience in the enforcement and defense of intellectual property rights and as expert witness at proceedings at the European Patent Office.

Langues
German, English

Agréments
German Patent Attorney
European Trademark and Design Attorney

Affiliations
German Patent Attorneys' Bar Association (PAK)
International Federation of Intellectual Property Attorneys (FICPI)
Royal Society of Chemistry (RSC)

Publications
“ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment”, co-author, Molecular Cancer Therapeutics, 2018.

“Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study”, co-author, ChemMedChem, 2017.

“Development of a Cyclin-Dependent Kinase Inhibitor Devoid of ABC Transporter-Dependent Drug Resistance”, co-author, British Journal of Cancer, 2013.

“Total synthesis and determination of the absolute stereochemistry of the squalene synthase inhibitors CJ-13,981 and CJ-13,982”, co-author, Tetrahedron Letters, 2009.

Go to publications

Contact

Dr. Alexander Bondke

Tel. +49 (0)89-2102320
Fax +49 (0)89-21949408

bondke@wallinger.de

vCard Download


sfy39587p00